Novartis announced today that it plans to add a new active pharmaceutical ingredient (API) manufacturing plant in North Carolina. The company expects the facility in Morrisville to focus on APIs for solid dosage tablets, capsules and RNA therapeutics. Novartis said its new facility marks a critical step to strengthen end-to-end U.S. production capability. It comes…
Novartis to build new radioligand therapy manufacturing site in Texas
Novartis announced today that it plans to establish a new radioligand therapy (RLT) manufacturing site in Denton, Texas. The purpose-built RLT site will mark Novartis’ fifth in the U.S. and first manufacturing facility in Texas. It comes as part of a planned $23 billion investment across the U.S. Novartis has, in the past couple of…
Novartis breaks ground on North Carolina facility
Novartis announced today that it broke ground on its more than 700,000-square-foot flagship manufacturing hub in North Carolina. The company said it is rapidly moving to construct its recently announced $771 million investment in the state. Its project features a new facility in Morrisville and a new site in Durham, encompassing two new facilities. The…
Novartis opens new manufacturing plant in California
Novartis announced today that it opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in California. The state-of-the-art site in Carlsbad marks the latest milestone in the company’s previously announced $23 billion investment in U.S. infrastructure over the next five years. Novartis says the Carlsbad facility opening allows it to seamlessly meet future demand for…
Novartis to expand U.S. manufacturing, R&D footprint with $23B investment
Novartis announced today that it plans to invest $23 billion over five years to expand its U.S.-based infrastructure. The company said its investment aims to ensure all key Novartis medicines for U.S. patients will be made in the U.S. Its financial commitment enables the company to expand on its current pharmaceutical manufacturing, research and technology…
Siemens Healthineers acquires Novartis molecular imaging business
Siemens Healthineers announced today that it completed the acquisition of Advanced Accelerator Applications Molecular Imaging from Novartis. The newly acquired unit is a European manufacturing and distribution network of diagnostic radiopharmaceuticals for positron emission tomography (PET) scans. According to a news release, it will be known as “Advanced Accelerator Applications, a Siemens Healthineers company.” Reports first…
Sanofi, Novartis among Time’s most sustainable companies
Pharma giants Sanofi and Novartis came in at No. 7 and 17, respectively, in Time magazine’s “Most Sustainable Companies of 2024” rankings. Overall, nearly 40 of the 500 companies on the list fell under the category of Chemicals, Drugs & Biotechnology. Other large pharma companies making it into the top half of the 500 included…
Novartis begins $256M Singapore expansion
Novartis announced last week that it broke ground on a biopharmaceutical manufacturing plant in Singapore. The company put forward a $256 million investment to begin the project, which will lead to the deployment of digital and automation solutions to enhance manufacturing productivity, improve operational efficiency, and upskill the workforce. Novartis said this site will focus…
Novartis opens new radioligand therapy manufacturing facility in Indianapolis
Novartis today announced the expansion of its radioligand therapy (RLT) manufacturing capabilities with a new facility in Indianapolis. The Basil, Switzerland–based pharma giant said it has received FDA approval for commercial manufacturing in Indianapolis of its RLT therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to treat advanced metastatic prostate cancer. The new 70,000-square foot facility…
Novartis’s Sandoz spin-off and Sanofi’s portfolio slim-down reflect pharma push toward specialization
The pharmaceutical trend toward increasing concentration appears to be gaining momentum. On September 15, Novartis shareholders approved the company’s proposed spinoff of Sandoz, the generics and biosimilars unit. The company anticipates the deal to close in early October. Similarly, Sanofi is also taking a scalpel to its operations, offloading a selection of its central nervous…